The IP Factor

Watson Laborarories Requests Declaratory Judgement that Teva’s Patent For Seasonique is Invalid Watson Laboratories Inc. has filed a declaratory judgment suit against Teva Women’s Health Inc., seeking a ruling that its bid to make a generic version of oral contraceptive Seasonique does not infringe a separate patent covering a lower dosage of the drug. Watson, the generics maker, filed its complaint Thursday in the U.S. District Court for the District of Nevada, disputing the validity of a “nearly identical” patent assigned to the Teva unit. THE CASE: Watson Laboratories, Inc. vs Teva Women’s Health, Inc. 3:10-cv-00115; filed February 25, 2010 in the District Court of Nevada

This entry was posted on Tuesday, March 2nd, 2010 at 11:29 am and is filed under Intellectual Property, Israel, Israel IP, Israel Patent, Patents, pharmaceuticals, pharmaceuticals and Biotechnology, Teva. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.